BMS 232632

Known as: 232632, BMS, BMS-232632, BMS232632 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2008
02420002008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Recommendations for a highly active antiretroviral therapy (HAART) in either pretreated patients or symptomatic patients with an… (More)
Is this relevant?
2003
2003
To evaluate the cross-resistance profile of the human immunodeficiency virus type 1 protease inhibitor (PI) atazanavir (BMS… (More)
Is this relevant?
2003
2003
A selective, accurate, and reproducible LC-MS-MS assay was developed for the determination of the HIV protease inhibitor… (More)
Is this relevant?
2003
2003
A selective, accurate, and reproducible LC/MS/MS assay was developed and validated for the determination of the HIV protease… (More)
Is this relevant?
2002
2002
The in vitro inhibition of wild-type human immunodeficiency virus (HIV) by combinations of lopinavir and six other protease… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
Review
2002
Review
2002
The introduction of HIV-1 protease inhibitors in 1995 ushered in the era of highly active antiretroviral therapy. For the first… (More)
Is this relevant?
2001
2001
BMS-232632 is a potent human immunodeficiency type 1 (HIV-1) protease inhibitor with a half-life that allows for once-daily… (More)
Is this relevant?
2001
2001
BMS-232632, an azapeptide HIV protease inhibitor, is in development by Bristol-Myers Squibb (BMS), under license from Novartis… (More)
Is this relevant?
2000
2000
BMS-232632 is an azapeptide human immunodeficiency virus type 1 (HIV-1) protease (Prt) inhibitor that exhibits potent anti-HIV… (More)
Is this relevant?
2000
2000
BMS-232632 is an azapeptide human immunodeficiency virus (HIV) type 1 (HIV-1) protease inhibitor that displays potent anti-HIV-1… (More)
Is this relevant?